These 10 Stocks Posted Double-, Triple-Digit Gains Last Week

2. CervoMed Inc. (NASDAQ:CRVO)

CervoMed saw its share prices increase by 191 percent on Friday versus its $2.21 close on March 7 following positive results from the extension phase of its phase 2b clinical study of Neflamapimod for the treatment of Dementia with Lewy Bodies (DLB).

A total of 159 participants enrolled in the initial phase of the study. Of the number, 152 completed the initial phase, and 149 entered the extension phase, during which all participants received Neflamapimod.

In a statement last week, John-Paul Taylor, professor of translational dementia research at Newcastle University in the UK, said that the results from the extension phase of the study were highly persuasive.

DLB is the third most common degenerative disease of the brain after Alzheimer’s disease (AD) and Parkinson’s disease. According to CRVO, patients with the disease accumulate protein deposits called Lewy bodies in the brain’s nerve cells. This negatively affects cognitive ability, including attention, judgment, and reasoning, along with motor function.